EP1109533A1 - Pulmonale verabreichung von in liposomen verkapseltem thc - Google Patents

Pulmonale verabreichung von in liposomen verkapseltem thc

Info

Publication number
EP1109533A1
EP1109533A1 EP00945490A EP00945490A EP1109533A1 EP 1109533 A1 EP1109533 A1 EP 1109533A1 EP 00945490 A EP00945490 A EP 00945490A EP 00945490 A EP00945490 A EP 00945490A EP 1109533 A1 EP1109533 A1 EP 1109533A1
Authority
EP
European Patent Office
Prior art keywords
composition
cannabinoid
thc
tetrahydrocannabinol
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00945490A
Other languages
English (en)
French (fr)
Inventor
Orlando Hung
Jiri Zamecnik
Pang N. Shek
Peter Tikuisis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minister of National Defence of Canada
UK Government
Original Assignee
Minister of National Defence of Canada
UK Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minister of National Defence of Canada, UK Government filed Critical Minister of National Defence of Canada
Publication of EP1109533A1 publication Critical patent/EP1109533A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00945490A 1999-07-08 2000-07-07 Pulmonale verabreichung von in liposomen verkapseltem thc Withdrawn EP1109533A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14279099P 1999-07-08 1999-07-08
US142790P 1999-07-08
PCT/CA2000/000805 WO2001003668A1 (en) 1999-07-08 2000-07-07 Pulmonary delivery of liposome-encapsulated cannabinoids

Publications (1)

Publication Number Publication Date
EP1109533A1 true EP1109533A1 (de) 2001-06-27

Family

ID=22501293

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00945490A Withdrawn EP1109533A1 (de) 1999-07-08 2000-07-07 Pulmonale verabreichung von in liposomen verkapseltem thc

Country Status (5)

Country Link
EP (1) EP1109533A1 (de)
JP (1) JP2003504321A (de)
AU (1) AU5958200A (de)
CA (1) CA2341035A1 (de)
WO (1) WO2001003668A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402020C (en) * 2000-03-09 2006-08-29 Gw Pharma Limited Pharmaceutical compositions
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
US20050079136A1 (en) * 2001-07-10 2005-04-14 Woolfe Austen John Aerosol formulations of delta tetrahydrocannabinol
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
CA2454644C (en) * 2002-08-14 2014-09-16 Gw Pharma Limited Cannabinoid liquid formulations for mucosal administration
WO2004037271A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with ps liposomes
WO2004037270A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
EP1696929A4 (de) * 2003-11-05 2010-02-24 Unimed Pharmaceuticals Inc Delta-9-thc-zusammensetzungen und verfahren zur behandlung von symptomen in zusammenhang mit multipler sklerose
MX2007007038A (es) 2004-12-09 2008-03-07 Insys Therapeutics Inc Formulacion de dronabinol en temperatura ambiente.
GB2431105A (en) 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
CA2682376C (en) 2007-03-30 2015-10-06 Hirofumi Takeuchi Transpulmonary liposome for controlling drug arrival
WO2009099670A2 (en) 2008-02-08 2009-08-13 Nektar Therapeutics Al, Corporation Oligomer-cannabinoid conjugates
WO2013009928A1 (en) 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
US10258601B1 (en) * 2013-08-22 2019-04-16 Stephen C. Perry Vaporizable cannabinoid compositions
US9855216B2 (en) * 2015-05-27 2018-01-02 Ghasem Amoabediny Targeted nano-liposome co-entrapping anti-cancer drugs
BR112018068986B1 (pt) * 2016-03-18 2023-03-21 Christopher Brian Reid Composição para reduzir a expressão oncógena de uma célula, tecido ou órgão de um indivíduo
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2018221739A1 (en) * 2017-02-15 2019-08-29 Molecular Infusions, Llc Formulations
CA3088312A1 (en) 2018-01-12 2019-07-18 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery
JP7326445B2 (ja) 2018-12-11 2023-08-15 ディスラプション・ラブズ・インコーポレイテッド 治療剤の送達のための組成物並びにその使用及び製造方法
WO2020124268A1 (en) * 2018-12-21 2020-06-25 Botaneco Inc. Cannabinoid formulations and methods of making same
US20210023005A1 (en) 2019-07-26 2021-01-28 Landsteiner Scientific S.A. De C.V. Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications
EP4021415A4 (de) * 2019-09-01 2023-10-25 Nextage Therapeutics Ltd. Cannabinoid mit zielgerichteten liposomen
CN114727960A (zh) 2019-10-03 2022-07-08 耶路撒冷希伯来大学伊森姆研究发展有限公司 数个脂质体大麻素及其用途
US20220395547A1 (en) * 2019-11-08 2022-12-15 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
US20220387352A1 (en) * 2020-07-29 2022-12-08 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
US20220031616A1 (en) * 2020-07-29 2022-02-03 Matthew HALPERT Aerosolized CBD Liposomes for the treatment of Asthma and other pulmonary inflammatory disorders
US20230131989A1 (en) * 2020-07-29 2023-04-27 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
WO2024025525A1 (en) * 2022-07-27 2024-02-01 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
NZ511568A (en) * 1998-11-12 2003-08-29 Frank G An inhalation system using lipids for the delivery of bioactive compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0103668A1 *

Also Published As

Publication number Publication date
WO2001003668A1 (en) 2001-01-18
AU5958200A (en) 2001-01-30
CA2341035A1 (en) 2001-01-18
JP2003504321A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
WO2001003668A1 (en) Pulmonary delivery of liposome-encapsulated cannabinoids
EP1888033B1 (de) Verfahren und zusammensetzung zur behandlung von entzündlichen erkrankungen
US9980959B2 (en) Method and composition for treating rhinitis
WO2019196129A1 (zh) 一种局部麻醉镇痛缓释递药系统及其制备方法和应用
US20090181080A1 (en) Oral cannabinnoid liquid formulations and methods of treatment
BE1005952A4 (fr) Liposomes.
WO2021196659A1 (zh) 糖基聚醚类化合物脂质体及其制备方法和药物
IL148241A (en) Composition for inhalation containing delta-9-tetrahydrocannabinol
WO1987005803A1 (en) COMPOSITIONS OF LIPOSOMES AND beta2-RECEPTOR ACTIVE SUBSTANCES
WO2021064730A1 (en) Liposomal cannabinoids and uses thereof
BG63327B1 (bg) Липозомен състав, съдържащ селегилин
WO1996022764A1 (en) Liposomes containing a corticosteroid
US20130005824A1 (en) Treatment of ischemic tissue
Tabak et al. Evaluation of a liposome system for the delivery of desferrioxamine to lungs in rats
JPH05501714A (ja) リポソーム組成物
KR101198201B1 (ko) 비염 치료를 위한 방법 및 조성물
CN117813081A (zh) 用于治疗普拉德-威利综合征的大麻二醇酸酯
CN1813905A (zh) 一种包覆辛夷挥发油纳米脂质体滴鼻剂

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030317

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030930